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Abstract  
BACKGROUND: It is unclear whether the glycated hemoglobin (HbA1c) assay accurately reflects 
glycemic control in patients with chronic kidney disease (CKD).  
AIM: To evaluate the usefulness of glycated albumin (GA) in diabetic CKD population with 
reference to glycemic control in comparison to HbA1c. 
MATERIALS AND METHODS: Totally 194 Diabetic CKD (Male: 126, Female: 68) patients who 
attended a private nephrology clinic, were taken for the study. The age ranged between 18 to 87 
years. Blood samples were collected in fasting state in all the patients and all biochemical 
estimations were done using fully automated analyzer.  
RESULTS: The mean estimated GFR levels were 82.47, 44.32, 24.13 and 10 ml/min/1.73 m
2
 in 
Group I, II, III & IV respectively. The GA levels were significantly increased when the eGFR levels 
have been decreased. Also the GA: HbA1c ratio differed significantly when compared between the 
groups I & II, I & III and group I & IV of CKD patients. 
CONCLUSION: GA estimation is a useful marker in assessment of short term glycemic control in 
stage III & IV (< 30 ml/min/1.73m
2
) diabetic CKD patients. GA: HbA1c ratio if routinely done may 
also become a useful marker in Diabetic CKD population in future. 
  
 
 
 
 
 
Introduction 
Glycosylated hemoglobin (HbAlc) is most 
often used as an intermediate indicator for blood 
glucose control in diabetics, and the Diabetes Control 
and Complications Trial (DCCT) [1], United Kingdom 
Prospective Diabetes Study (UKPDS) [2] and 
Kumamoto Study [3] have greatly valued HbAlc as an 
indicator for blood glucose control. However, HbAlc 
levels are influenced by other factors in addition to 
blood glucose. Of these other factors, the life span of 
erythrocytes is particularly important. The HbA 1c 
assay provides falsely low readings in diabetic 
patients with end-stage renal disease (ESRD) [4–6]. 
This phenomenon likely relates to the shortened red 
blood cell survival observed in ESRD, with reduced 
time available for glucose and hemoglobin to 
chemically interact   [7]. In contrast, the glycated 
albumin (GA) assay appears to more accurately 
reflect recent glycemic control in diabetic patients with 
ESRD who are on dialysis   [4–6]. The GA assay 
mainly reflects serum glucose control over the 
preceding 17-day period (maximum 60 days), relative 
to the HbA1c assay which predominantly reflects 
glycemic control over the preceding 30 days 
(maximum 120 days). 
   It is unclear whether the HbA1c  assay 
accurately reflects glycemic control in patients with 
moderate and advanced stages of chronic kidney 
disease (CKD), particularly those with stages 3,4 and 
stage 5 CKD   [8] . This is an important concern since 
HbA1c has recently been recommended as a 
screening test for diabetes mellitus, the number of 
patients with CKD far exceeds those with ESRD and 
improved glucose control reduces progression of 
CKD, benefits diabetic retinal disease [9-11] and 
possibly benefits atherosclerosis as well [12]. 
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As on date, no studies have been conducted 
to establish the correlation between glucose and 
glycemic control markers so as to predict the most 
accurately representing biomarker in Indian patients 
with CKD stages 3, 4 and 5. Hence, the present study 
undertaken to determine whether GA is a better 
biomarker than HbA1c for glycemic control in Indian 
patients with CKD stages 3, 4 and 5.  
 
Materials and Methods 
Patients  
  Totally 194 CKD (Male: 126, Female: 68) 
patients who attended a private nephrology OPD clinic 
were taken for the study. The age ranged between 18 
and 87 years. The duration of diabetes mellitus was 6-
20 years. The patients were categorized into four 
groups according to GFR estimation by MDRD 
formula, Group I > 60 ml/min/1.73 m
2
 (n:  46) (CKD 
stage 2), Group II 30-59 ml/min/1.73 m
2 
(n: 62) (CKD 
stage 3), Group III 16-29 ml/min/1.73 m
2 
(n: 46) (CKD 
stage 4) & Group IV >15 ml/min/1.73 m
2
 (n: 40) (CKD 
stage 5). Subjects who received pancreas transplants, 
history of suggestive hypoglycemia, recent 
hospitalization, presence of sepsis, those with ESRD 
currently receiving any form of dialysis therapy were 
excluded. All the patients included in the study were 
on self-monitoring of glucose at home, done thrice in a 
week, as fasting, 2hr post lunch and pre dinner. In the 
present study, we have taken into account the 
average blood glucose in the previous one month 
period for those who have completed one month of 
self-monitoring. Measurement of GA and HbA1c 
levels were determined in all study subjects. Informed 
and written consent were obtained from all the 
patients. Estimated GFR was calculated using the 4-
variable MDRD equation. Statistical analysis was 
done by using Medcalc statistical software. 
 
GA and HbA1c  Assays  
Serum albumin concentrations were 
measured using the bromocresol purple (BCP) assay 
(modified BCP method using the Lucica (GA-L kit; 
Asahi Kasei Pharma Corp., Tokyo, Japan). GA was 
measured using the Lucica GA-L kit (Asahi Kasei 
Pharma Corp.) on serum samples. This kit uses an 
enzymatic method that converts GA to glycated amino 
acids. The glycated amino acids are then oxidized 
with formation of hydrogen peroxide, which is coupled 
to a dye yielding a purple-blue color. The GA and Hb 
A1c analysis were performed on the automated 
‘Biosystems A15’ instrument (Biosystems, USA) and 
HbA1C by Bio RadD10. To measure the percent of 
GA, the conversion formula supplied with the Lucica 
GA-L assay kit was applied to all study subjects; the 
formula used to calculate percent of GA is [([GA 
concentration/albumin]/1.14  × 100) + 2.9].The blood 
glucose estimation done by glucose oxidase method 
[13] and serum creatinine by alkaline picrate method 
[14]. GA to HbA1C ratio accurately compares the two 
parameters, more than individual comparison. 
 
Results 
Blood samples were collected from 194 
diabetic patients with various stages of GFR. The 
clinical characteristics of the four groups are 
summarized in the table. The mean estimated GFR 
levels were 82.47, 44.32, 24.13 and 10 ml/min/1.73 
m
2
 in Group I, II, III & IV respectively. Mean age & sex 
in various groups as Group I (49.13± 12.64 ) (N: 46 
M:30  F:16),   Group II ( 58.92 ± 7.55) (N: 62  M:38    
F:24), Group III (57.26 ± 10.06) ( N: 46 M:28   F: 
18)and Group IV (54.9 ± 9.16) ( N: 40 M: 32  F: 8). 
The mean blood urea  of groups I,II,III and IV were 
24.17± 5.64,56.21 ± 18.72, 80.30 ± 22.56 and 109.25 
± 54.05 respectively. The mean ± SD of serum 
creatinine levels were 0.96 ± 0.17, 2.90±0.19, 
3.66±0.54 and 5.10±1.73 in group I, II, III and IV 
respectively. The average total protein (Albumin, 
globulin) of group I,II , III and IV were 7.29 (3.60, 
3.69), 6.57 (3.12, 3.45), 6.87 (3.17, 3.70) and 6.54 
(3.1, 3.44) respectively. 
Mean (SD) HbA1c (%) and GA (%) 
concentrations were 9.96 (3.63) and 27.84 (13.51) in 
group I, 9.68 (1.43) and 38.76 (6.73) in group II, 8.46 
(1.96) and 43.28 (14.46) in group III & 8.63 (1.89) and 
49.84 (8.77) in group IV. GA: HbA1c ratios for all the 
groups were studied. This ratio helps to compare the 
two parameters among the various groups. The GA: 
HbA1c ratio differed significantly when compared 
between groups I &II, I &III and I & IV of CKD patients 
(P = <0.0001, P = <0.0001 & P =<0.0001 
respectively). 
 
 
Table 1: Clinical characteristics among four groups. 
 
Group 
1 2 3 4 
1&2 
P Value 
 
1&3 
P Value 
1&4 
P Value 
> 60 ml/min/1.73m
2
 
(n= 46) 
30 – 59 ml/min/1.73m
2 
(n= 62) 
16 – 29 ml/min/1.73m
2 
(n= 46) 
< 15 ml/min/1.73m
2 
(n= 40) 
Age 49.13 ± 12.64 58.93 ± 7.56 57.26 ± 10.07 54.9 ± 9.16 <0.0001 0.0010 0.0190 
S. Creatinine, mg/dl 0.965 ± 0.17 2.90 ± 0.19 3.66 ± 0.54 5.10 ± 1.73 <0.0001 <0.0001 <0.0001 
B. Glucose, mg/dl 248.1 ± 100.9 284.9 ± 71.35 301 ± 96.72 398.9 ± 114.6 0.8475 0.0246 0.002 
HbA1c 9.96 ± 3.63 9.68 ± 1.43 8.46 ± 1.96 8.63 ± 1.89 0.0130 0.0156 0.0402 
GA % 27.84 ± 13.51 38.76 ± 6.73 43.28 ± 14.46 49.84 ± 8.77 <0.0001 <0.0001 <0.0001 
GA: HbA1c % 2.79 ± 0.79 4 ± 1.18 5.11 ± 1.14 5.77 ± 0.69 <0.0001 <0.0001 <0.0001 
Glucose/GA 8.91 ± 6.18 7.35 ± 2.96 6.95 ± 6.40 7.76 ± 2.38 0.0850 0.1386 0.2715 
Glucose/HbA1c 24.90 ± 8.81 29.43 ± 7.61 35.57 ± 10.94 37.31 ± 11.19 0.0051 <0.0001 <0.0001 
GFR  82.47 ± 14.46 44.32 ± 7.89 24.13 ± 3.74 10 ± 2.90 <0.0001 <0.0001 <0.0001 
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For group II, III and IV, HbA1c and estimated 
GFR levels were significantly decreased and the 
creatinine & blood glucose levels were increased 
significantly when compared with the group I. The GA 
levels were significantly increased when the eGFR 
have been decreased. 
 
Discussion 
To the best of our knowledge, there are no 
reports available in Indian population comparing 
glycated hemoglobin with glycated albumin in various 
stages of chronic kidney disease. The regular 
monitoring of the diabetes is highly warranted to all 
the diabetic patients, especially patients with chronic 
kidney disease to avoid the progression of CKD to 
ESRD. The HbA1c assay has marked limitations in 
diabetic patients with ESRD, with significant 
underestimation of recent glycemic control compared 
to blood glucose and the GA assay [4–6]. It is unclear 
whether the HbA1c assay accurately reflects glycemic 
control in patients with moderate and advanced 
stages of chronic kidney disease (CKD). In the 
present study it has been clearly observed that HbA1c 
is not an accurate marker in the moderate and severe 
stages of chronic kidney disease and the same be  
replaced by  GA as an alternative marker and  similar 
observation was noted in the previous study 
conducted on samples of New Zealand population 
[15].  
The present analyses reiterate the earlier 
observations by demonstrating that the GA: HbA1c 
ratio differs among patients with stages 3, 4 or 5 CKD. 
This suggests that the HbA1c assay results are falsely 
reduced in stages 3, 4 & 5 CKD patients. It has been 
reported in earlier study [16] that HbA1c assay may 
be less accurate in diabetic subjects with advanced 
CKD. The present study also confirms that the 
estimation of HbA1c in diabetic CKD patients (stages 
3, 4 & 5) may lead to underestimate the glycemic 
control. 
GA/HbA1c ratio is significantly higher when 
blood glucose increased [17].The present study also 
observed higher GA/HbA1c ratio when the blood 
glucose increased. In the present study it is observed 
that HbA1c does not accurately predict the glycemic 
control with worsening kidney function. It is found in 
the present study that GA is a better marker for 
glycemic control in severe kidney disease (CKD 
stages 3, 4 and 5) than in early phases of decreasing 
GFR. 
Remarkably, GA is not only a marker for 
glycemic control in CKD but also has a biological 
impact in progression of the disease. Elevated levels 
of GA induce the metabolic disorders like retinopathy, 
nephropathy, neuropathy and coronary artery disease 
[18]. Therefore, whether the GA/HbA1c ratio reflects 
insulin secretory function or elevated levels of GA 
persuade insulin secretory dysfunction needs more 
attention. 
In conclusion, GA is a better marker for 
detecting short term glycemic control in Indian 
patients with CKD stages 4 & 5 (Group III & IV) and 
the assessment of glycemic control by HbA1c in those 
patients might lead to underestimation. The 
GA/HbA1c ratio has been directly proportional to the 
glucose levels in all stages of CKD. As the population 
studied in the present study is relatively small and 
large population studies are needed to confirm our 
results. 
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